Generic Name and Formulations:
Mesalamine 250mg, 500mg; controlled-rel caps.
Shire US, Inc.
Indications for PENTASA:
Mildly-to-moderately active ulcerative colitis.
Swallow whole; may open caps and sprinkle entire contents onto applesauce or yogurt, consume immediately. 1g four times daily for up to 8 weeks.
Discontinue if acute intolerance syndrome is suspected. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Renal disease; monitor SCr, BUN, proteinuria. Hepatic impairment. Pregnancy (Cat.B). Nursing mothers.
May interfere with urinary normetanephrine test by liquid chromatography; consider alternative assay.
Diarrhea, headache, nausea, abdominal pain, dyspepsia, vomiting, rash; nephrotoxicity.
Caps 250mg—240; 500mg—120
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D